Current Use of Nephelometric Quantification of Serum Free Light Chains (FLCs) in the Management of Plasma Cell Dyscrasias, and the Potential Benefits of Point-Of-Care Testing.

2.50
Hdl Handle:
http://hdl.handle.net/11287/583468
Title:
Current Use of Nephelometric Quantification of Serum Free Light Chains (FLCs) in the Management of Plasma Cell Dyscrasias, and the Potential Benefits of Point-Of-Care Testing.
Authors:
Veale, Dave; McCulloch, Rory; O'Connor, John; Parfitt, Ceri; Cudmore, Adrian; Kerr, Paul
Abstract:
Quantitative nephelometric assays detecting polyclonal sheep anti-sera and serum FLCs (e.g. Freelite®) are the gold standard method for monitoring FLC secretion from myeloma cells, but are only available in central laboratories. The frequent delay between venepuncture and assay results can affect diagnosis, treatment decisions and patient communication. Second generation point-of-care assays have been developed using monoclonal antibodies to FLCs, producing results in 10 minutes (e.g. Seralite®). This study investigates potential impact on care of patients with plasma cell dyscrasias.
Issue Date:
Apr-2015
URI:
http://hdl.handle.net/11287/583468
Type:
Meetings and Proceedings
Language:
en
Description:
Conference poster displayed at British Society for Haematology Annual Scientific Meeting, Edinburgh, 20-22 April 2015.
Sponsors:
Dave Veale funded by Exeter Leukaemia Fund.
Appears in Collections:
2015 RD&E publications; Exeter Clinical Laboratory International (Blood Sciences, Genetics, Cellular Pathology & Microbiology); Clinical Haematology

Full metadata record

DC FieldValue Language
dc.contributor.authorVeale, Daveen
dc.contributor.authorMcCulloch, Roryen
dc.contributor.authorO'Connor, Johnen
dc.contributor.authorParfitt, Cerien
dc.contributor.authorCudmore, Adrianen
dc.contributor.authorKerr, Paulen
dc.date.accessioned2015-12-09T11:59:22Zen
dc.date.available2015-12-09T11:59:22Zen
dc.date.issued2015-04en
dc.identifier.urihttp://hdl.handle.net/11287/583468en
dc.descriptionConference poster displayed at British Society for Haematology Annual Scientific Meeting, Edinburgh, 20-22 April 2015.en
dc.description.abstractQuantitative nephelometric assays detecting polyclonal sheep anti-sera and serum FLCs (e.g. Freelite®) are the gold standard method for monitoring FLC secretion from myeloma cells, but are only available in central laboratories. The frequent delay between venepuncture and assay results can affect diagnosis, treatment decisions and patient communication. Second generation point-of-care assays have been developed using monoclonal antibodies to FLCs, producing results in 10 minutes (e.g. Seralite®). This study investigates potential impact on care of patients with plasma cell dyscrasias.en
dc.description.sponsorshipDave Veale funded by Exeter Leukaemia Fund.en
dc.language.isoenen
dc.titleCurrent Use of Nephelometric Quantification of Serum Free Light Chains (FLCs) in the Management of Plasma Cell Dyscrasias, and the Potential Benefits of Point-Of-Care Testing.en
dc.typeMeetings and Proceedingsen
All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.